On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology sector.

On the news front, the company announced on June 1 a proposed share award plan aimed at improving its incentive mechanism by attracting, motivating, and retaining core employees and service providers. The plan is subject to shareholder approval at the annual general meeting scheduled for June 29. Meanwhile, the company is accelerating commercialization of its core GLP-1 receptor agonist product, which was included in the National Medical Insurance Drug Catalog effective January 1, supporting broader market penetration. Additionally, the company is exploring new application areas including companion animal diabetes and obesity, with related veterinary clinical trial applications formally accepted in early 2026.

Within the Biotechnology sector, the overall sector traded weaker. Among individual stocks, AKESO down 4.79%, 3SBIO down 3.56%, Innovent Bio down 2.98%, BeiGene down 2.90%, SKB Bio down 4.16%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)